Genetically-Engineered Pigs as a Source of Blood Products

Area of Science:

• Biotechnology
• Transfusion Medicine
• Xenotransplantation

Background:

• Whole blood and its components are vital for treating various medical conditions, with millions of transfusions and plasma-derived product administrations annually.
• The increasing demand for blood products necessitates exploring alternative, more sustainable sources beyond human donors.
• Current blood product systems face challenges in reliability, cost-effectiveness, and meeting escalating clinical needs.

Purpose of the Study:

• To provide an overview of the blood product economy.
• To assess the feasibility of using genetically engineered pigs as a source for clinical-grade blood products.
• To highlight the specific need for these products in patients receiving pig organ grafts.

Main Methods:

• Review of the existing blood product market and economic factors.
• Assessment of the potential of genetically engineered pigs for blood product generation.
• Analysis of clinical requirements and feasibility for human recipients.

Main Results:

• Genetically engineered pigs present a viable alternative source for blood products, addressing limitations of the current donor-dependent system.
• The demand for blood products is substantial and growing globally.
• A specific need exists for these products in patients undergoing xenotransplantation with pig organs.

Conclusions:

• Genetically engineered pigs hold significant potential to meet the growing global demand for reliable and cost-effective blood products.
• This innovative approach could revolutionize transfusion medicine and support the advancement of xenotransplantation.
• Further research and development are warranted to fully realize the benefits of porcine-derived blood products for human recipients.